Fair Value Calculator Fair Value Calculator
EN DE

HLscience Co (239610) Fair Value & Analysis

Healthcare · KR · Market cap 28.5B KRW

HC HLscience Co 239610 · KQ
Price5,320 KRW
Fair Value5,889 KRW
Upside+10.7%
Quality39/100
Watch HLscience Co for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 3,887 KRW – 7,361 KRW

Fair value as of: Jul 7, 2026

From 1 valuation models · updated today

Fair value updated Jul 7, 2026 — revised from 29,196 KRW to 5,889 KRW (−79.8%) since Jun 24, 2026. Share price −11.3% over the past month.

Price vs Fair Value (12 months)

12,720 KRW 5,260 KRW Fair Value 5,889 KRW Jun 2025 Jul 2026

12‑month range 5,260 KRW – 12,720 KRW · fair‑value band 3,887 KRW – 7,361 KRW · the 5,320 KRW price screens below the 5,889 KRW fair value. As of Jul 7, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

HLscience Co (239610) currently trades at 5,320 KRW, while our model-based Fair Value estimate is 5,889 KRW — implying the stock looks roughly 10.7% undervalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, HLscience Co generated revenue of 13.8B KRW at a net margin of -82.1%. Revenue declined 58.0% year over year. It earns a return on equity of -13.1%. Fundamentals as of Jul 7, 2026

Our scenario range runs from 3,887 KRW (bear case) to 7,361 KRW (bull case); at 5,320 KRW, the current price sits within that range. The share trades about 61% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at 11%, 239610 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 13.8B KRW
Revenue growth (YoY) -58.0%
Net margin -82.1%
Return on equity -13.1%
Free cash flow −7.6B KRW FY2025
Operating margin -105%
More key figures
EPS growth (YoY) -94.8%

Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.

About the company

HLscience Co., Ltd. manufactures and sells health functional foods in South Korea. The company offers organic barley grassjuice powder one day, queen's pomegranate jin, Super LuzieA+ Astaxanthin, Dr. Superkhan, HL-JOINT 100 for Joint & Cartilage Premium, Dr. Green Propolis, morosil diet fit, skin master secret, enerlinger vitamin D, PS300 formulated by doctor, Skin Master P-estro, and Dr. Prebiotics Plus. It also provides CDMO, contract development organization and contract research organization, contract manufacturing organization, quality assurance system, and funding services. Its products are used for antioxidant/skin health/immune function, female menopausal health/skin moisturizing/UV care, liver health, cartilage and joint health/bone health, body fat reduction/energy metabolism, brain health/blood circulation improvement, and gut health applications. The company was founded in 2000 and is headquartered in Hwaseong-si, South Korea.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

HLscience Co reported revenue of 16.7B KRW in FY2025 versus 104B KRW in FY2021, a compound −36.7%/yr. Reported net income was −11.9B KRW in FY2025.

Revenue −36.7%/yr
FY21 104B KRW
FY22 52.8B KRW
FY23 25.6B KRW
FY24 17.7B KRW
FY25 16.7B KRW
Net income
FY21 13.5B KRW
FY22 1.6B KRW
FY23 −1.4B KRW
FY24 −7.9B KRW
FY25 −11.9B KRW

Is 239610 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "HLscience Co Fair Value". https://www.fairvalue-calculator.com/stock/239610

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 1276 HK$57.85 HK$29.84 -48%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,863 ₹1,039 -44%
Zoetis Inc Z1TS34 R$24.45 R$6.33 -74%
Hansoh Pharmaceutical Group 3692 HK$29.58 HK$18.75 -37%
Divi's Laboratories Limited DIVISLAB ₹6,788 ₹2,035 -70%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,421 ₹1,504 -66%
Cipla Limited CIPLA ₹1,433 ₹1,035 -28%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,098 ₹507.31 -54%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,272 ₹720.15 -43%
PharmaEssentia Corporation 6446 937.00 TWD 322.35 TWD -66%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is HLscience Co (239610) undervalued?
As of Jul 7, 2026, our model estimates a fair value of 5,889 KRW versus a price of 5,320 KRW — about +11% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 239610?
Our model-based fair value for HLscience Co is 5,889 KRW (as of Jul 7, 2026), built from audited fundamentals. The current price is 5,320 KRW.
What is the quality score of 239610?
HLscience Co has a Quality Score of 39/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of HLscience Co (239610)?
HLscience Co reported trailing-twelve-month revenue of about 13.8B KRW (latest available figure, as of Jul 7, 2026).
What is the net profit margin of 239610?
The net profit margin of HLscience Co is about -82.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.